Proteomics

Dataset Information

0

Proteomic analysis to examine the functional consequences of intratumor heterogeneity


ABSTRACT: To examine the functional consequences of intratumor heterogeneity, subclonal populations (SCPs) were derived from the MDA-MB-468 triple-negative breast cancer cell line. Characterization of these SCPs revealed considerable variation in SCP tumor forming capacity with SCP #32 (SCP32) having an exceptional high tumor forming capacity. To investigate the proteomic differences between tumors of SCP32 and other SCPs, in TMT1, isobaric tandem mass tag (TMT) labeling combined with LC-MS/MS (TMT-MS) was performed on tumors of SCP03, SCP29 and SCP32 (n = 3 each) collected at 2 months post transplantation. In TMT2, isobaric tandem mass tag (TMT) labeling combined with LC-MS/MS (TMT-MS) was performed on tumors of the parental MDA-MB-468 cell line (n = 2), and both barcoded and non-barcoded versions SCP29 and SCP32 (two each) collected at 2 months post transplantation.

INSTRUMENT(S): Orbitrap Fusion Lumos, Orbitrap Fusion

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Epithelial Cell

DISEASE(S): Breast Adenocarcinoma

SUBMITTER: Tian Zhang  

LAB HEAD: Steven Gygi

PROVIDER: PXD022325 | Pride | 2022-02-16

REPOSITORIES: Pride

altmetric image

Publications


Intratumoral heterogeneity has been described for various tumor types and models of human cancer, and can have profound effects on tumor progression and drug resistance. This study describes an in-depth analysis of molecular and functional heterogeneity among subclonal populations (SCPs) derived from a single triple-negative breast cancer cell line, including copy number analysis, whole-exome and RNA sequencing, proteome analysis, and barcode analysis of clonal dynamics, as well as functional as  ...[more]

Similar Datasets

2023-05-10 | PXD033001 | Pride
2020-12-16 | PXD019495 | Pride
2023-03-10 | PXD033865 | Pride
2023-10-11 | PXD043473 | Pride
2020-07-12 | PXD017852 | Pride
2021-06-10 | PXD013024 | Pride
2020-07-13 | PXD017853 | Pride
2021-02-20 | GSE110908 | GEO
2023-01-17 | PXD030225 | Pride
2020-04-30 | PXD018252 | Pride